Six-month evaluation of the benefits of the low-dose combined oral contraceptive chlormadinone acetate 2mg/ethinylestradiol 0.03 mg in young women: Results of the prospective, Observational, non-interventional, multicentre TeeNIS study

Clinical Drug Investigation

Volumn 30, Issue 4, 2010, Pages 211-220

  Anthuber, Sabine ^a   Schramm, Georg A K ^b   Heskamp, Marie Luise S ^b  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b GRÜNENTHAL GMBH   (Germany)

Author keywords

Estrogen receptor agonists; Ethinylestradiolchlormadinone, therapeutic use; Oral contraceptives, therapeutic use; Progesterone receptor agonists, therapeutic use; Therapeutic use

Indexed keywords

ANALGESIC AGENT; CHLORMADINONE ACETATE PLUS ETHINYLESTRADIOL;

ACNE; ADOLESCENT; ADULT; AMENORRHEA; ARTICLE; BACKACHE; BLEEDING; BLOOD CLOTTING DISORDER; BODY WEIGHT; BREAKTHROUGH BLEEDING; BREAST DISEASE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; FEMALE; GERMANY; GROUPS BY AGE; HEADACHE; HUMAN; JOB PERFORMANCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MENSTRUATION DISORDER; MOOD CHANGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PHYSICIAN; PILL; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEBORRHEA; SELF ESTEEM; SKIN DISEASE; SPOTTING; THROMBOPHILIA; THROMBOSIS; TREATMENT DURATION;

ACNE VULGARIS; ADOLESCENT; CHILD; CHLORMADINONE ACETATE; CONTRACEPTIVES, ORAL, COMBINED; DYSMENORRHEA; ETHINYL ESTRADIOL; FEMALE; GERMANY; HUMANS; MENSTRUATION DISTURBANCES; PROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77949549266     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11532910-000000000-00000     Document Type: Article

References (31)

1. Mosher WD, Martinez GM, Chandra A, et al. Use of contraception and use of family planning services in the United States: 1982-2002. Adv Data 2004; (350): 1-36
2. Hickey M, Balen A. Menstrual disorders in adolescence: investigation and management. Hum Reprod Update 2003; 9: 493-504
3. Slap GB. Menstrual disorders in adolescence. Best Pract Res Clin Obstet Gynaecol 2003; 17: 75-92
4. Klein JR, Litt IF. Epidemiology of adolescent dysmenorrhoea. Pediatrics 1981; 68: 661-664
5. Ziv A, Boulet JR, Slap GB. Utilization of physician offices by adolescents in the United States. Pediatrics 1999; 104: 35-42
6. Neinstein LS. Menstrual problems in adolescents. Med Clin North Am 1990; 74: 1181-1203
7. Bergfeld WF. The evaluation and management of acne: economic considerations. J Am Acad Dermatol 1995; 32: S52-6
8. Zahradnik HP, Goldberg J, Andreas JO. Efficacy and safety of the new antiandrogenic oral contraceptive Belara®. Contraception 1998; 57: 103-109
9. Worret I, Arp W, Zahradnik HP, et al. Acne resolution rates: results of a single-blind, randomised, controlled, parallel phase III trial with EE/CMA (Belara-) and EE/LNG (Microgynon®). Dermatology 2001; 203: 38-44
10. Schramm G, Steffens D. Contraceptive efficacy and tolerability of chlormadinone acetate 2mg/ethinylestradiol 0.03 mg (Belara®). Clin Drug Investig 2002; 22: 221-231
11. Schramm G, Steffens D. A 12-month evaluation of the CMA-containing oral contraceptive Belara®: efficacy, tolerability and anti-androgenic properties. Contraception 2003; 67: 305-312
12. Zahradnik HP. Belara® - a reliable oral contraceptive with additional benefits for health and efficacy in dysmenorrhoea. Eur JContracept ReprodHealth Care 2005; 10 Suppl. 1: 12-18
13. Kerscher M, Reuther T, Bayrhammer J, et al. Effect of an oral contraceptive containing chlormadinone and ethinylestradiol on acne-prone skin of women of different age groups. Clin Drug Investig 2008; 28 (11): 703-711
14. Schramm G, Heckes B. Switching hormonal contraceptives to a chlormadinone acetate-containing oral contraceptive: the Contraceptive Switch Study. Contraception 2007; 76: 84-90
15. Feige A, Rempen A, Wü rfel W, et al. Frauenheilkunde: Fortpflanzungsmedizin Geburtsmedizin Onkologie Psychosomatik (Gebundene Ausgabe). In: Geisthö vel F, editor. Munich: Elsevier GmbH, 2005
16. Runnebaum B, Rabe T. Gynä kologische Endokrinologie. Berlin: Springer-Verlag, 1994: 413
17. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, et al., editors. Contraceptive technology. 19th rev ed. New York: Ardent Media, 2007
18. Spona J, Binder N, Hö schen K, et al. Contraceptive efficacy and safety of a low-dose oral contraceptive (0.03 mg ethinyl oestradiol and 2mg chlormadinone acetate) Belara, over three medication cycles. Eur J Contracept Reprod Health Care 2008; 13: 39-48
19. Vandenbroucke JP, van der Meer FJ, Helmerhorst FM, et al. Factor V Leiden: should we screen oral contraceptive users and pregnant women? BMJ 1996; 313: 1127-1130
20. Cardiovascular disease and steroid hormone contraception: report of a WHO scientific group. WHO Tech Rep Ser 1998; 877: 1-89
21. Schramm G, Heckes B. The COSS-study: switching hormonal contraceptives to a combined oral contraceptive containing chlormadinone acetate (2mg) and ethinyl estradiol (0.03mg) [poster no. P029]. 9th Congress of the European Society of Contraception, 2006Mar 3-6; Istanbul
22. Feldman W, Hodgson C, Corber S, et al. Health concerns and health-related behaviours of adolescents. CMAJ 1986; 134: 489-493
23. Hamani Y, Sciaki-Tamir Y, Deri-Hasid R, et al. Misconceptions about oral contraception pills among adolescents and physicians. Hum Reprod 2007; 22: 3078-3083
24. Gallo MF, Nanda K, Grimes DA, et al. 20 mg versus <20 mg estrogen combined oral contraceptives for contraception. Cochrane Database Syst Rev 2008; 4: CD003989
25. Zahradnik HP, Hanjalic-Beck A, Groth K. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from dysmenorrhea: a review. Contraception. In press
26. Proctor M, Farquhar C. Dysmenorrhoea. Clin Evid 2002; 7: 1639-1653
27. French L. Dysmenorrhea. Am Fam Physician 2005; 71(2): 285-291
28. Bock K, Heskamp ML, Schramm G. Convincing effect of CMA on dysmenorrhoea and other cycle-related disorders [in German]. Gyne 2008; 8: 219-225
29. Tan HH. Topical antibacterial treatments for acne vulgaris: comparative review and guide to selection. Am J Clin Dermatol 2004; 5: 79-84
30. Kerscher M. Hormonal contraception-prospects and limitations in dermatocosmetic indications [in German]. Gynä kol Endokrinol 2009; 7: 17-24
31. Druckmann R. Profile of the progesterone derivative chlormadinone acetate: pharmacodynamic properties and therapeutic applications. Contraception 2009;79 (4): 272-281